ImmunoGen
| Public | |
| Traded as | NASDAQ: IMGN |
| Industry | healthcare |
| Founded | 1981 |
| Headquarters | Waltham, Massachusetts, United States |
Number of employees | 280 |
| Website |
www |
ImmunoGen, Inc. (NASDAQ: IMGN) is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.[1]
An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.
Payload technology
The ADCs currently in the clinic with ImmunoGen technology employ one of the company's maytansinoid cell-killing agents, either DM1 or DM4, or one of the company's DNA-acting IGN payloads.
- DM1 attached to an antibody with ImmunoGen's thioether linker is called "emtansine" in its INN name (e.g., ado-trastuzumab emtansine).
- DM1 attached to an antibody with ImmunoGen's SPP linker is called "mertansine".
- DM4 attached with ImmunoGen's SPDB linker is called "ravtansine" e.g.,
- indatuximab ravtansine(BT062) targeting multiple myeloma,
- anetumab ravtansine(BAY94-9343) targeting mesothelin (to treat mesothelioma), starting phase II trial in 2016[2]
- coltuximab ravtansine (SAR3419) targeting CD19 to treat acute lymphoblastic leukemia (ALL).[3]
- DM4 attached with ImmunoGen's sSPDB linker is called "soravtansine" (e.g., mirvetuximab soravtansine).
Collaborations & licensing
The company also selectively outlicenses limited use of its technology to other companies. Companies licensing ImmunoGen's technology include Amgen, Bayer HealthCare, Biotest, Genentech/Roche, Eli Lilly, Novartis, Sanofi, and Takeda.[4] Roche's Kadcyla (ado-trastuzumab emtansine) utilizes ImmunoGen's ADC technology. It has been approved and launched in a number of countries, including the US, where it is marketed by Genentech, a member of the Roche Group.[5][6] In October 2015, the company disclosed that Kadcyla had failed to meets its primary endpoint in the Phase II/III GATSBY trial investigating the second line treatment of HER2-positive advanced gastric cancer.[7]
Pipeline
ImmunoGen uses its ADC technology to develop its own product candidates. These include;[4]
- IMGN853, (mirvetuximab soravtansine) targeting FRα, and using DM4.[8]
- IMGN529, targeting CD37 for Non-Hodgkin lymphoma (NHL).[9]
- IMGN289, targeting EGFR[10]
- IMGN779, a CD33-Targeted Antibody-Drug Conjugate (ADC) with a new DNA-Alkylating agent acts on AML Cells.[9]
References
- ↑ "ImmunoGen Inc., Inc. stock price Yahoo Finance". Finance.yahoo.com. Retrieved 2014-03-09.
- ↑ MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial Designed to Support Registration of Anetumab Ravtansine
- ↑ A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- 1 2 http://www.immunogen.com/
- ↑ http://www.gene.com/
- ↑ http://www.kadcyla.com/
- ↑ http://www.genengnews.com/gen-news-highlights/roche-s-kadcyla-fails-phase-ii-iii-trial-for-gastric-cancer/81251888/
- ↑ Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.
- 1 2 ASH Dec 2015
- ↑ A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors